After falling just short of the $20 billion figure in annual sales for three straight years, AbbVie's Humira finally topped the elusive mark—and did it by a comfortable margin—generating $20.7 billion ...

(Bloomberg) — AbbVie Inc. made its arthritis treatment Humira the best-selling medication in the world. Now, after years of wrangling, rivals are finally set to bring a wave of lower-cost versions to ...

Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” for the field, the drug—dubbed Cyltezo—has struggled to gain traction thanks ...